Thermo Fisher to Support ImmuPharma’s Kapiglucagon Program

ImmuPharma plc, a specialist drug discovery and development company, has selected Thermo Fisher Scientific as the contract development and manufacturing organization (CDMO) to support its Kapiglucagon program.

The selection of Thermo Fisher aims to support the next stages of pharmaceutical development and IND-enabling preparation for Kapiglucagon, a proprietary glucagon prodrug being developed for Type 1 diabetes applications, with a focus on overcoming the inherent physicochemical limitations of native glucagon. The program is designed to improve solubility and formulation stability, with potential application in dual-hormone artificial pancreas systems and other glucagon-based therapeutic settings.

ImmuPharma believes Kapiglucagon represents an important strategic opportunity. The Company has previously stated that it intends to pursue an accelerated development plan for Kapiglucagon, including evaluation of a 505(b)(2) regulatory pathway, and that the program is supported by the recently approved funding initiative intended to advance the asset over the next two years.

Dr Sébastien Goudreau, Chief Scientific Officer of ImmuPharma, said, “We are pleased to select Thermo Fisher as DP CDMO for the Kapiglucagon program. This represents an important step in strengthening the CMC foundation of the program as we continue to advance Kapiglucagon toward clinical development.”